pS2 and response to adjuvant hormone therapy in primary breast cancer.

We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Spyratos, F., Andrieu, C., Hacène, K., Chambon, P., Rio, M. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968674/
https://www.ncbi.nlm.nih.gov/pubmed/8297741
_version_ 1782134791890534400
author Spyratos, F.
Andrieu, C.
Hacène, K.
Chambon, P.
Rio, M. C.
author_facet Spyratos, F.
Andrieu, C.
Hacène, K.
Chambon, P.
Rio, M. C.
author_sort Spyratos, F.
collection PubMed
description We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy.
format Text
id pubmed-1968674
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19686742009-09-10 pS2 and response to adjuvant hormone therapy in primary breast cancer. Spyratos, F. Andrieu, C. Hacène, K. Chambon, P. Rio, M. C. Br J Cancer Research Article We reviewed 319 primary breast tumours for cytosolic pS2 content, with a median follow-up of 6 years. pS2 status correlated positively with oestradiol and progesterone receptors and negatively with Scarff, Bloom and Richardson grade. pS2 positivity was associated with longer overall survival, particularly in patients who received hormone therapy, in whom pS2 status was also predictive of the response to therapy. Nature Publishing Group 1994-02 /pmc/articles/PMC1968674/ /pubmed/8297741 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Spyratos, F.
Andrieu, C.
Hacène, K.
Chambon, P.
Rio, M. C.
pS2 and response to adjuvant hormone therapy in primary breast cancer.
title pS2 and response to adjuvant hormone therapy in primary breast cancer.
title_full pS2 and response to adjuvant hormone therapy in primary breast cancer.
title_fullStr pS2 and response to adjuvant hormone therapy in primary breast cancer.
title_full_unstemmed pS2 and response to adjuvant hormone therapy in primary breast cancer.
title_short pS2 and response to adjuvant hormone therapy in primary breast cancer.
title_sort ps2 and response to adjuvant hormone therapy in primary breast cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968674/
https://www.ncbi.nlm.nih.gov/pubmed/8297741
work_keys_str_mv AT spyratosf ps2andresponsetoadjuvanthormonetherapyinprimarybreastcancer
AT andrieuc ps2andresponsetoadjuvanthormonetherapyinprimarybreastcancer
AT hacenek ps2andresponsetoadjuvanthormonetherapyinprimarybreastcancer
AT chambonp ps2andresponsetoadjuvanthormonetherapyinprimarybreastcancer
AT riomc ps2andresponsetoadjuvanthormonetherapyinprimarybreastcancer

Ejemplares similares